HDACs and MYC in medulloblastoma: how do HDAC inhibitors control MYC-amplified tumors?

Neuro Oncol. 2021 Feb 25;23(2):173-174. doi: 10.1093/neuonc/noaa292.

Authors

Tomoko Shofuda¹, Yonehiro Kanemura^{1

2}

Affiliations

¹ Department of Biomedical Research and Innovation, Institute for Clinical Research, National Hospital Organization Osaka National Hospital, Osaka, Japan.
² Department of Neurosurgery, National Hospital Organization Osaka National Hospital, Osaka, Japan.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Cell Line, Tumor
Cerebellar Neoplasms* / drug therapy
Cerebellar Neoplasms* / genetics
Histone Deacetylase Inhibitors / therapeutic use*
Humans
Medulloblastoma* / drug therapy
Medulloblastoma* / genetics
Proto-Oncogene Proteins c-myc / genetics

Substances

Histone Deacetylase Inhibitors
Proto-Oncogene Proteins c-myc